[go: up one dir, main page]

CO5241355A1 - Forma envasada de composiciones farmaceuticas nucleosidicas activas para vacunas contra la hepatitis - Google Patents

Forma envasada de composiciones farmaceuticas nucleosidicas activas para vacunas contra la hepatitis

Info

Publication number
CO5241355A1
CO5241355A1 CO00001261A CO00001261A CO5241355A1 CO 5241355 A1 CO5241355 A1 CO 5241355A1 CO 00001261 A CO00001261 A CO 00001261A CO 00001261 A CO00001261 A CO 00001261A CO 5241355 A1 CO5241355 A1 CO 5241355A1
Authority
CO
Colombia
Prior art keywords
active
packaged form
hepatitis
nucleosidic
against hepatitis
Prior art date
Application number
CO00001261A
Other languages
English (en)
Spanish (es)
Inventor
Gillian Frances Atkinson
Ronald James Boon
G Vandepapelie Pierre
Anne Cecile Wettendorf Martine
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of CO5241355A1 publication Critical patent/CO5241355A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CO00001261A 1999-01-12 2000-01-12 Forma envasada de composiciones farmaceuticas nucleosidicas activas para vacunas contra la hepatitis CO5241355A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9900630 1999-01-12

Publications (1)

Publication Number Publication Date
CO5241355A1 true CO5241355A1 (es) 2003-01-31

Family

ID=10845878

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00001261A CO5241355A1 (es) 1999-01-12 2000-01-12 Forma envasada de composiciones farmaceuticas nucleosidicas activas para vacunas contra la hepatitis

Country Status (19)

Country Link
EP (1) EP1140163A2 (fr)
JP (1) JP2002534438A (fr)
KR (1) KR20010090011A (fr)
CN (1) CN1391482A (fr)
AR (1) AR022250A1 (fr)
AU (1) AU760574B2 (fr)
BR (1) BR9916893A (fr)
CA (1) CA2359110A1 (fr)
CO (1) CO5241355A1 (fr)
CZ (1) CZ20012544A3 (fr)
HK (1) HK1041434A1 (fr)
HU (1) HUP0105070A2 (fr)
IL (1) IL144186A0 (fr)
NO (1) NO20013337L (fr)
NZ (1) NZ512890A (fr)
PL (1) PL349347A1 (fr)
TR (1) TR200102024T2 (fr)
WO (1) WO2000041463A2 (fr)
ZA (1) ZA200105690B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE335510T1 (de) 1998-05-22 2006-09-15 Ottawa Health Research Inst Methoden und produkte zur induzierung mukosaler immunität
PT1103564E (pt) 1998-07-31 2009-03-13 Int Inst Cancer Immunology Inc Antigénios de cancro com base no produto do gene supressor de tumor wt1
US20040097703A1 (en) 2001-03-22 2004-05-20 Haruo Sugiyama Wt1 modified peptide
WO2003028757A1 (fr) * 2001-09-28 2003-04-10 Haruo Sugiyama Nouvelle methode pour induire des lymphocytes t specifiques d'antigenes
JPWO2003028758A1 (ja) * 2001-09-28 2005-01-13 治夫 杉山 抗原特異的ｔ細胞の誘導方法
TWI275392B (en) * 2002-04-08 2007-03-11 Bristol Myers Squibb Co Low dose liquid entecavir formulations and use
MXPA05004588A (es) 2002-10-29 2005-12-14 Coley Pharmaceutical Group Ltd Metodos y productos relacionados con el tratamiento y prevencion de infeccion de virus de hepatitis c.
WO2004053104A2 (fr) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. Acides nucleiques 5'cpg et leurs methodes d'utilisation
CN100443117C (zh) * 2003-05-13 2008-12-17 深圳康泰生物制品股份有限公司 一种治疗性乙型肝炎的疫苗制剂、其制备方法及其用途
US8541167B2 (en) 2004-06-03 2013-09-24 Saint Louis University Methods and compositions for vaccination
WO2008104133A1 (fr) * 2007-02-28 2008-09-04 Centro De Ingeniería Genética Y Biotecnología Thérapie combinée pour le traitement de l'hépatite b chronique
US12409221B2 (en) * 2018-12-24 2025-09-09 Grand Theravac Life Sciences (Nanjing) Co., Ltd. Pharmaceutical preparation for treating hepatitis b, preparation method therefor and use thereof
JPWO2022215737A1 (fr) * 2021-04-07 2022-10-13

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE159031T1 (de) * 1989-07-25 1997-10-15 Smithkline Biolog Antigene sowie verfahren zu deren herstellung
KR20010041629A (ko) * 1998-03-09 2001-05-25 장 스테판느 혼합 백신 조성물

Also Published As

Publication number Publication date
KR20010090011A (ko) 2001-10-17
NO20013337D0 (no) 2001-07-05
WO2000041463A2 (fr) 2000-07-20
TR200102024T2 (tr) 2001-12-21
AR022250A1 (es) 2002-09-04
JP2002534438A (ja) 2002-10-15
PL349347A1 (en) 2002-07-15
AU2100900A (en) 2000-08-01
HUP0105070A2 (hu) 2002-04-29
ZA200105690B (en) 2002-09-25
BR9916893A (pt) 2001-11-20
HK1041434A1 (zh) 2002-07-12
CZ20012544A3 (cs) 2002-01-16
NO20013337L (no) 2001-08-17
NZ512890A (en) 2003-09-26
CA2359110A1 (fr) 2000-07-20
CN1391482A (zh) 2003-01-15
EP1140163A2 (fr) 2001-10-10
IL144186A0 (en) 2002-05-23
WO2000041463A3 (fr) 2000-11-09
AU760574B2 (en) 2003-05-15

Similar Documents

Publication Publication Date Title
AR029655A1 (es) Mejoras en formulaciones en pasta
BR0108435A (pt) Formulação e uso de entecavir de baixa dose
AR018410A1 (es) Uso de una composicion para la manufactura de un medicamento que se usa para la prevencion o tratamiento de un estado agudo de asma y/o asma intermitentey/o episodios de asma cronico y metodo para la prevencion o tratamiento de un estado agudo de asma y/o asma intermitente y/o episodios de asma cron
CO5241355A1 (es) Forma envasada de composiciones farmaceuticas nucleosidicas activas para vacunas contra la hepatitis
UY26724A1 (es) Métodos y composiciones para tratar el virus de la hepatitis c
BR0107869A (pt) Composições farmacêuticas eletrogiradas
ES2167061T3 (es) Formas de dosificacion para mejorar la disfuncion erectil en pacientes de sexo masculino.
MX9202407A (es) Composicion farmaceutica que contiene un compuesto de alilamina como el agente activo y proceso para su preparacion.
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
ES2156839T1 (es) Medicamento que contiene alginato e implante para tratar la fibrosis.
ECSP045102A (es) Formulación farmacéutica que contiene 3-(3-dimetilamino-1-etil-2-metil-propil)fenol y proporciona una liberación retardada del ingrediente activo
AR005281A1 (es) Composicion farceutica oral , procedimientos para su manufactura y uso de esa composicion farmaceutica para la preparacion de medicamentos. .
MX9200992A (es) Composicion farmaceutica que tiene como ingrediente activo 3-[2-(dimetilamino)etil]-n-metil-1h-indol-5-metanosulfonamida y procedimiento para su preparacion.
AR034900A1 (es) Uso de una cantidad eficaz de un inhibidor de pde4 y un agente anticolinergico, bien en forma combinada sola o por separado, composiciones farmaceuticas que los comprenden, metodo para prepararlas, y uso de una composicion que comprende una cantidad eficaz de un inhibidor de pde4, una cantidad efica
ES2160163T3 (es) Composiciones farmaceuticas a base de derivados de la clase de los taxanos.
AR033688A1 (es) Composicion parenteral reconstituible
AR026254A1 (es) El uso de una preparacion de liberacion controlada para la preparacion de un medicamento para aumentar la dosis o la exposicion sistemica de un farmaco queinhibe la fosfodiesterasa 4
ES2150404T3 (es) Composiciones farmaceuticas de tizoxanida y nitozoxanida.
AR045263A1 (es) Metodo, kit y composicion farmaceutica para tratar infecciones virales
CA2385755A1 (fr) Prevention du cancer colorectal
UY26514A1 (es) " composición para el tratamiento de tejidos danados".
UY26595A1 (es) Formulaciones de entecavir de dosis bajas y uso
ECSP003685A (es) Formulaciones orales de liberacion controlada
ES2185310T3 (es) Agente antivirico herbario.
AR027287A1 (es) Gonadotrofina

Legal Events

Date Code Title Description
FC Application refused